Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma

Daniel Y. Wang, Zeynep Eroglu, Alpaslan Ozgun, Paul D. Leger, Shilin Zhao, Fei Ye, Jason J. Luke, Richard W Joseph, Rizwan Haq, Patrick A. Ott, F. Stephen Hodi, Jeffrey A. Sosman, Douglas B. Johnson, Elizabeth I. Buchbinder

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Anti-PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti-PD-1. We retrospectively reviewed 488 patients treated with anti-PD-1 from three academic centers and identified 36 patients with acquired resistance, defined as disease progression following objective response. The incidence, timing, disease sites, post-progression survival (PPS), and outcomes were evaluated descriptively. The acquired resistance cohort consisted of 67% with more than 1 feature of poor prognosis (stage M1c, elevated LDH, or brain metastasis), and 67% had previously received ipilimumab. Partial and complete responses were achieved in 89% (n = 32) and 11% (n = 4) of patients, respectively, and median time to resistance (progression-free survival; PFS) was 11.1 months (range 4.3-32.8 months). Most progression was isolated (78% of patients, n = 28) and occurred while receiving therapy (78%, n = 28). The median PPS was 12.8 months (range 0.1-51.8 months), and the median overall survival was 33.7 months. Among isolated progressors, 15 received localized therapy (12 with surgery, 3 with radiation). Patients with isolated versus systemic progression exhibited a trend for improved PPS (P = 0.081), and patients with an initial PFS ≥ 15 months showed significant PPS improvement (P = 0.036). Two patients experienced subsequent responses to anti-PD-1 resumption. In conclusion, acquired resistance to anti-PD-1 was frequently associated with excellent clinical outcomes and often presented as isolated progression amenable to localized therapy (surgery or radiation) or systemic progression sensitive to therapy resumption.

Original languageEnglish (US)
Pages (from-to)357-362
Number of pages6
JournalCancer immunology research
Volume5
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Melanoma
Survival
Therapeutics
Radiation
Disease-Free Survival
Disease Progression
Neoplasm Metastasis
Incidence
Brain

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Wang, D. Y., Eroglu, Z., Ozgun, A., Leger, P. D., Zhao, S., Ye, F., ... Buchbinder, E. I. (2017). Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma. Cancer immunology research, 5(5), 357-362. https://doi.org/10.1158/2326-6066.CIR-16-0287

Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma. / Wang, Daniel Y.; Eroglu, Zeynep; Ozgun, Alpaslan; Leger, Paul D.; Zhao, Shilin; Ye, Fei; Luke, Jason J.; Joseph, Richard W; Haq, Rizwan; Ott, Patrick A.; Hodi, F. Stephen; Sosman, Jeffrey A.; Johnson, Douglas B.; Buchbinder, Elizabeth I.

In: Cancer immunology research, Vol. 5, No. 5, 01.05.2017, p. 357-362.

Research output: Contribution to journalArticle

Wang, DY, Eroglu, Z, Ozgun, A, Leger, PD, Zhao, S, Ye, F, Luke, JJ, Joseph, RW, Haq, R, Ott, PA, Hodi, FS, Sosman, JA, Johnson, DB & Buchbinder, EI 2017, 'Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma', Cancer immunology research, vol. 5, no. 5, pp. 357-362. https://doi.org/10.1158/2326-6066.CIR-16-0287
Wang, Daniel Y. ; Eroglu, Zeynep ; Ozgun, Alpaslan ; Leger, Paul D. ; Zhao, Shilin ; Ye, Fei ; Luke, Jason J. ; Joseph, Richard W ; Haq, Rizwan ; Ott, Patrick A. ; Hodi, F. Stephen ; Sosman, Jeffrey A. ; Johnson, Douglas B. ; Buchbinder, Elizabeth I. / Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma. In: Cancer immunology research. 2017 ; Vol. 5, No. 5. pp. 357-362.
@article{034f160be4b84faaabc13818f3f1e8bc,
title = "Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma",
abstract = "Anti-PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti-PD-1. We retrospectively reviewed 488 patients treated with anti-PD-1 from three academic centers and identified 36 patients with acquired resistance, defined as disease progression following objective response. The incidence, timing, disease sites, post-progression survival (PPS), and outcomes were evaluated descriptively. The acquired resistance cohort consisted of 67{\%} with more than 1 feature of poor prognosis (stage M1c, elevated LDH, or brain metastasis), and 67{\%} had previously received ipilimumab. Partial and complete responses were achieved in 89{\%} (n = 32) and 11{\%} (n = 4) of patients, respectively, and median time to resistance (progression-free survival; PFS) was 11.1 months (range 4.3-32.8 months). Most progression was isolated (78{\%} of patients, n = 28) and occurred while receiving therapy (78{\%}, n = 28). The median PPS was 12.8 months (range 0.1-51.8 months), and the median overall survival was 33.7 months. Among isolated progressors, 15 received localized therapy (12 with surgery, 3 with radiation). Patients with isolated versus systemic progression exhibited a trend for improved PPS (P = 0.081), and patients with an initial PFS ≥ 15 months showed significant PPS improvement (P = 0.036). Two patients experienced subsequent responses to anti-PD-1 resumption. In conclusion, acquired resistance to anti-PD-1 was frequently associated with excellent clinical outcomes and often presented as isolated progression amenable to localized therapy (surgery or radiation) or systemic progression sensitive to therapy resumption.",
author = "Wang, {Daniel Y.} and Zeynep Eroglu and Alpaslan Ozgun and Leger, {Paul D.} and Shilin Zhao and Fei Ye and Luke, {Jason J.} and Joseph, {Richard W} and Rizwan Haq and Ott, {Patrick A.} and Hodi, {F. Stephen} and Sosman, {Jeffrey A.} and Johnson, {Douglas B.} and Buchbinder, {Elizabeth I.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1158/2326-6066.CIR-16-0287",
language = "English (US)",
volume = "5",
pages = "357--362",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma

AU - Wang, Daniel Y.

AU - Eroglu, Zeynep

AU - Ozgun, Alpaslan

AU - Leger, Paul D.

AU - Zhao, Shilin

AU - Ye, Fei

AU - Luke, Jason J.

AU - Joseph, Richard W

AU - Haq, Rizwan

AU - Ott, Patrick A.

AU - Hodi, F. Stephen

AU - Sosman, Jeffrey A.

AU - Johnson, Douglas B.

AU - Buchbinder, Elizabeth I.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Anti-PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti-PD-1. We retrospectively reviewed 488 patients treated with anti-PD-1 from three academic centers and identified 36 patients with acquired resistance, defined as disease progression following objective response. The incidence, timing, disease sites, post-progression survival (PPS), and outcomes were evaluated descriptively. The acquired resistance cohort consisted of 67% with more than 1 feature of poor prognosis (stage M1c, elevated LDH, or brain metastasis), and 67% had previously received ipilimumab. Partial and complete responses were achieved in 89% (n = 32) and 11% (n = 4) of patients, respectively, and median time to resistance (progression-free survival; PFS) was 11.1 months (range 4.3-32.8 months). Most progression was isolated (78% of patients, n = 28) and occurred while receiving therapy (78%, n = 28). The median PPS was 12.8 months (range 0.1-51.8 months), and the median overall survival was 33.7 months. Among isolated progressors, 15 received localized therapy (12 with surgery, 3 with radiation). Patients with isolated versus systemic progression exhibited a trend for improved PPS (P = 0.081), and patients with an initial PFS ≥ 15 months showed significant PPS improvement (P = 0.036). Two patients experienced subsequent responses to anti-PD-1 resumption. In conclusion, acquired resistance to anti-PD-1 was frequently associated with excellent clinical outcomes and often presented as isolated progression amenable to localized therapy (surgery or radiation) or systemic progression sensitive to therapy resumption.

AB - Anti-PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti-PD-1. We retrospectively reviewed 488 patients treated with anti-PD-1 from three academic centers and identified 36 patients with acquired resistance, defined as disease progression following objective response. The incidence, timing, disease sites, post-progression survival (PPS), and outcomes were evaluated descriptively. The acquired resistance cohort consisted of 67% with more than 1 feature of poor prognosis (stage M1c, elevated LDH, or brain metastasis), and 67% had previously received ipilimumab. Partial and complete responses were achieved in 89% (n = 32) and 11% (n = 4) of patients, respectively, and median time to resistance (progression-free survival; PFS) was 11.1 months (range 4.3-32.8 months). Most progression was isolated (78% of patients, n = 28) and occurred while receiving therapy (78%, n = 28). The median PPS was 12.8 months (range 0.1-51.8 months), and the median overall survival was 33.7 months. Among isolated progressors, 15 received localized therapy (12 with surgery, 3 with radiation). Patients with isolated versus systemic progression exhibited a trend for improved PPS (P = 0.081), and patients with an initial PFS ≥ 15 months showed significant PPS improvement (P = 0.036). Two patients experienced subsequent responses to anti-PD-1 resumption. In conclusion, acquired resistance to anti-PD-1 was frequently associated with excellent clinical outcomes and often presented as isolated progression amenable to localized therapy (surgery or radiation) or systemic progression sensitive to therapy resumption.

UR - http://www.scopus.com/inward/record.url?scp=85018450781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018450781&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-16-0287

DO - 10.1158/2326-6066.CIR-16-0287

M3 - Article

VL - 5

SP - 357

EP - 362

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 5

ER -